BridgeMD
Tests treatment safety and results for Irritable Bowel Syndrome
Official title Efficacy of Esketamine for Patients With Irritable Bowel Syndrome
ClinicalTrials.gov ID: NCT06788444
What this study is testing
What is Esketamine?
Esketamine is an investigational medicine, being studied as a potential treatment for irritable bowel syndrome.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To explore the efficacy of a single low dose of esketamine for patients with irritable bowel syndrome (IBS).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60
You may be able to join if
- Age of 18 - 60 years;
- American Society of Anesthesiologists (ASA) physical status of I - II;
- Body Mass Index (BMI) of 15 - 30;
- Scheduled for colonoscopy;
- Positive screening results according to the Rome IV diagnostic criteria for IBS;
You likely can't join if
- GastrointestinalTract (GI) bleeding;
- Any organic lesions confirmed by clinical examination, laboratory examination or colonoscopy；
- A previous diagnosis of colon cancer, infammatory bowel disease or coeliac disease;
- A history of weight loss (at least 10%) within six months;
- A history of abdominal surgery (other than hernia repair or appendectomy);
- Participate in other clinical trials within 3 months;
See the full eligibility criteria
- Age of 18 - 60 years;
- American Society of Anesthesiologists (ASA) physical status of I - II;
- Body Mass Index (BMI) of 15 - 30;
- Scheduled for colonoscopy;
- Positive screening results according to the Rome IV diagnostic criteria for IBS;
- Patients who met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for Anxiety disorder (ANXD) and/or major depressive disorder (MDD) .
- GastrointestinalTract (GI) bleeding;
- Any organic lesions confirmed by clinical examination, laboratory examination or colonoscopy；
- A previous diagnosis of colon cancer, infammatory bowel disease or coeliac disease;
- A history of weight loss (at least 10%) within six months;
- A history of abdominal surgery (other than hernia repair or appendectomy);
- Participate in other clinical trials within 3 months;
- Patients older than 55 years of age who have not undergone a colonoscopy in the past 5 years；
- Mental disorder patients with severe personality disorder, active suicidal ideation and history of self-harm within 1 year;
- Allergy or any contraindications to the drugs used in the study, such as severe cardiovascular disease, refractory hypertension, or hyperthyroidism;
- Drinking more than 50 units (1 unit refers to 10ml of pure alcohol) per week;
- Pregnancy or breastfeeding.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.